Inhibitory effect of Jab1-specific shRNA on the progression of human laryngeal carcinoma xenografts nude mice
10.3760/cma.j.issn.1673-0860.2012.05.012
- VernacularTitle:Jab1基因沉默对裸鼠人喉癌移植瘤生长影响的研究
- Author:
Hai-Xia LI
1
;
Hua CAO
Author Information
1. 河南大学淮河医院
- Keywords:
Laryngeal neoplasms;
Carcinoma,squmous cell;
Peptide hydrolases;
Intracellular signaling peptides and proteins;
Gene therapy;
Models,animal
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2012;47(5):406-410
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the antitumour efficacy of shRNA plasmid specifically targeting Jab1 gene.Methods The nude mouse tumor model was made by subcutaneous injection of human laryngeal carcinoma Hep-2 cells.The tumor growth was monitored after intratumoral injection of pJab1,pKB plasmids and saline.Jab1 and p27 expressions in tumour tissues were examined by immunohistochemistry stainingand RT-PCR.Results Mean volume of the pJab1 -treated tomors was(267.60 ± 88.19) mm3,significantly less than that of tumors treated with pKB plasmids( 832.20 ± 140.39)mm3 or saline(895.40 ± 145.93) mm3( F =36.73,P ＜ 0.001 ).Immunohistochemistry showed that the expression of Jab1 protein was significantly reduced in the pJab1-treated group(32.40％ ± 5.59％) compared to the control groups,whereas the expression rate of p27 protein in the pJab1 group(76.80％ ±6.30％ ) was significantly increased compared to the control groups( P ＜ 0.001 ).The down regulation of Jab1 protein by pJab1 plasmid was consistent with mRNA expression confirmed by RT-PCR.The level of Jab1 mRNA level in the pJab1-treated group( 0.65 ±0.03) was significantly lower than the control groups(F=558.00,P＜0.001),however,p27 mRNA,was 0.80 ±0.02,had no significant alteration(F=1.52,P＞0.05).Conclusions The pJab1 plasmid results in downregulation of Jab1 in an xenograft tumour model of human laryngeal carcinoma Hep-2 cells and significantly inhibits the tumour growth in vivo.This suggests that pJab1 plasmid specifically targeting Jab1 gene expression could be an effective therapy for human laryngeal carcinoma.
